Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation
Kfir Oved, Liraz Olmer, Yonat Shemer‐Avni, et al.
EClinicalMedicine (2020) Vol. 29-30, pp. 100651-100651
Open Access | Times Cited: 140

Showing 1-25 of 140 citing articles:

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
E G Levin, Yaniv Lustig, Carmit Cohen, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 24
Open Access | Times Cited: 1083
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers
Yaniv Lustig, Einav Sapir, Gili Regev‐Yochay, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 9, pp. 999-1009
Open Access | Times Cited: 330
Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays
Thomas Perkmann, Nicole Perkmann‐Nagele, Thomas Köller, et al.
Microbiology Spectrum (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 176
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
Laith J. Abu‐Raddad, Hiam Chemaitelly, Peter Coyle, et al.
EClinicalMedicine (2021) Vol. 35, pp. 100861-100861
Open Access | Times Cited: 173
The role of children in the spread of COVID-19: Using household data from Bnei Brak, Israel, to estimate the relative susceptibility and infectivity of children
Itai Dattner, Yair Goldberg, Guy Katriel, et al.
PLoS Computational Biology (2021) Vol. 17, Iss. 2, pp. e1008559-e1008559
Open Access | Times Cited: 171
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
Chava Perry, Efrat Luttwak, R. Balaban, et al.
Blood Advances (2021) Vol. 5, Iss. 16, pp. 3053-3061
Open Access | Times Cited: 159
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
Itzchak Levy, Anat Wieder-Finesod, Vladyslav Litchevsky, et al.
Clinical Microbiology and Infection (2021) Vol. 27, Iss. 12, pp. 1851-1855
Open Access | Times Cited: 158
BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignancies
Katrin Herzog Tzarfati, Odit Gutwein, Arie Apel, et al.
American Journal of Hematology (2021) Vol. 96, Iss. 10, pp. 1195-1203
Open Access | Times Cited: 155
Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population
Jonathan J. Lau, Samuel M. S. Cheng, Kathy Leung, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 348-357
Open Access | Times Cited: 145
How to interpret and use COVID-19 serology and immunology tests
David S. Y. Ong, Paraskevi C. Fragkou, Valentijn A. Schweitzer, et al.
Clinical Microbiology and Infection (2021) Vol. 27, Iss. 7, pp. 981-986
Open Access | Times Cited: 128
Anti-spike antibody response to natural SARS-CoV-2 infection in the general population
Jia Wei, Philippa C. Matthews, Nicole Stoesser, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 118
Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
Gili Regev‐Yochay, Sharon Amit, Moriah Bergwerk, et al.
The Lancet Regional Health - Europe (2021) Vol. 7, pp. 100150-100150
Open Access | Times Cited: 114
Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay
Elena Riester, Peter Findeisen, Johannes Kolja Hegel, et al.
Journal of Virological Methods (2021) Vol. 297, pp. 114271-114271
Open Access | Times Cited: 106
Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy
Omer Nir, A. Schwartz, Shlomi Toussia‐Cohen, et al.
American Journal of Obstetrics & Gynecology MFM (2021) Vol. 4, Iss. 1, pp. 100492-100492
Open Access | Times Cited: 106
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial
Dean Follmann, Holly Janes, Olive D. Buhule, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 9, pp. 1258-1265
Open Access | Times Cited: 106
Comparison of Seroconversion in Children and Adults With Mild COVID-19
Zheng Quan Toh, Jeremy Anderson, Nadia Mazarakis, et al.
JAMA Network Open (2022) Vol. 5, Iss. 3, pp. e221313-e221313
Open Access | Times Cited: 85
Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections
Laith J. Abu‐Raddad, Hiam Chemaitelly, Houssein H. Ayoub, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 70
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Ohad Benjamini, Lior Rokach, Gilad Itchaki, et al.
Haematologica (2021) Vol. 107, Iss. 3, pp. 625-634
Open Access | Times Cited: 95
Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
Yael Peled, Eilon Ram, Jacob Lavee, et al.
The Journal of Heart and Lung Transplantation (2021) Vol. 41, Iss. 2, pp. 148-157
Open Access | Times Cited: 94
SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals
Peter Coyle, Hiam Chemaitelly, Mohamed Ali Ben Hadj Kacem, et al.
iScience (2021) Vol. 24, Iss. 6, pp. 102646-102646
Open Access | Times Cited: 89
Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar
Andrew Jeremijenko, Hiam Chemaitelly, Houssein H. Ayoub, et al.
Emerging infectious diseases (2021) Vol. 27, Iss. 5, pp. 1343-1352
Open Access | Times Cited: 88
BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study
Galia Rahav, Yaniv Lustig, Jacob Lavee, et al.
EClinicalMedicine (2021) Vol. 41, pp. 101158-101158
Open Access | Times Cited: 78
Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in haematopoietic stem cell transplantation recipients
Noga Shem‐Tov, Ronit Yerushalmi, Ivetta Danylesko, et al.
British Journal of Haematology (2021) Vol. 196, Iss. 4, pp. 884-891
Open Access | Times Cited: 65
Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study
Sarah M. Bartsch, Kelly J. O’Shea, Kevin L. Chin, et al.
The Lancet Public Health (2022) Vol. 7, Iss. 4, pp. e356-e365
Open Access | Times Cited: 62
Predictors of Nonseroconversion after SARS-CoV-2 Infection
Wei‐Min Liu, Ronnie M. Russell, Frédéric Bibollet‐Ruche, et al.
Emerging infectious diseases (2021) Vol. 27, Iss. 9, pp. 2454-2458
Open Access | Times Cited: 60
Page 1 - Next Page

Scroll to top